Incidence of acute phase reactions (APRs) in patients with advanced cancer or multiple myeloma (MM) And bone metastases/lesions following treatment with denosumab or zoledronic acid (ZA) (#815)
Nina Singh RN
1
,
Cynthia Campbell-Baird RN, OCN
2
,
Hans Polderdijk RN
3
,
Stacey Harrelson RN
4
,
Judith Buechel RN
5
,
Tap Maniar MD
6
- Sydney Haematology and Oncology Clinics Clinical Trials Unit, Sydney Adventist Hospital, Wahroonga, NSW, Australia
- Penn State Milton S. Hershey Medical Center, Hershey, PA, USA
- HagaZiekenhuis-Leyenburg, Den Haag, Netherlands
- Carolina Urologic Research Center, Myrtle Beach, South Carolina, USA
- Haematology and Oncology, Innsbruck University Hospital, Inssbruck, Austria
- Amgen Inc., Thousand Oaks, CA, USA